Revolution Medicines RMC-6236 Phase 1 KRAS Inhibitor 2023

Phase 1 clinical trial data for RMC-6236, a first-in-class KRAS-selective inhibitor, evaluating safety, pharmacokinetics, and anti-tumor activity in 131 patients with KRAS-mutant solid tumors. The drug demonstrated dose-dependent exposure, favorable tolerability, and preliminary evidence of anti-tumor activity across multiple cancer types including pancreatic, lung, and colorectal cancers.